Navidea Biopharmaceuticals

526 articles with Navidea Biopharmaceuticals

• Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

  3/8/2018

  Navidea Biopharmaceuticals Inc. announced its financial results for the fourth quarter of 2017. Navidea reported total revenues for the quarter of $395,000.

• Navidea to Host Moderated Q&A Webcast with Management

  2/2/2018

  Navidea announced today that it will hold an online Question & Answer (Q&A) Session with Jed Latkin, Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of Navidea, on Tuesday February 13, 2018 at 5:00 p.m. Eastern Time.

• Navidea Biopharmaceuticals to Present at Biotech Showcase 2018

  12/20/2017

  Dr. Michael Goldberg, Chief Executive Officer of Navidea, will be giving a presentation and meeting with investors.

• Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results

  11/8/2017

  Navidea reported total revenues for the quarter of $224,000.

• Navidea to Present Late-Breaking Abstract at American College of Rheumatology Annual Meeting

  11/2/2017

  CSO of Navidea, will present a poster of an abstract, titled, “Evaluation of Intravenous Injection of Tc 99m Tilmanocept in Static Planar Gamma Emission Imaging and Fused SPECT/CT Imaging for Rheumatoid Arthritis” and provide an overview of Navidea’s development pipeline.

• Navidea Biopharmaceuticals Schedules Third Quarter 2017 Earnings Conference Call and Business Update

  10/31/2017

  Navidea announced it will host a conference call on Wednesday, November 8, 2017 at 8:30am E.T. to discuss its financial results for the third quarter 2017, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended September 30, 2017.

• Navidea Signs Letter of Intent to Sublicense NAV4694 Worldwide Development Rights

  10/30/2017

  Cerveau, and/or their fully controlled subsidiary, will act as a designated party for the rights resulting from the relationship between Navidea and Beijing Sinotau Medical Research Co., Ltd. (Sinotau), a subsidiary of Sinotau Pharmaceutical Group.

• Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A With Management

  8/31/2017

• Navidea Reports Second Quarter 2017 Financial Results

  8/9/2017

• Navidea Enters Exclusive License And Distribution Agreement For India With Sayre Therapeutics

  6/20/2017

• Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK In Europe

  6/12/2017

• Navidea Reports First Quarter 2017 Financial Results

  5/10/2017

• Navidea Provides Corporate Update And Reports Full Year 2016 Results

  3/30/2017

• Navidea Completes Sale Of North American Rights Of Lymphoseek To Cardinal Health

  3/6/2017

• Navidea Reports 2016 Third Quarter Financial Results

  11/2/2016

• Navidea To Announce Third Quarter 2016 Financial Results On November 3, 2016

  10/27/2016

• Struggling Navidea Appoints a New CEO

  9/27/2016

• Navidea Achieves $1 Million In Lymphoseek Commercial Milestones

  9/22/2016

• Navidea’s Lymphoseek Receives Positive Opinion In Europe For A New Reduced Mass Vial

  9/16/2016

• Navidea To Hold Investor Update Call

  9/7/2016